Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That Seeking Alpha article should send some shorts scrambling for shares next week! Squeeze them shorties. Watch 'em squirm!
Giddy Up, ICLDD!!!
Does this imply a short squeeze is coming for ICLDD?
It's on my TD Ameritrade website!
"Cash flow positive"...I like that phrase!
You mean all I have to do is buy at these 2 cent a share prices and wait 6 months or a year and I've got a potential 100 bagger?!
OK...I'll wait it out! No problem!
ICLD is Alive and Kickin'!
OWCP should have some relevant news relating to the safety study before much longer. That should give the stock a boost with good results.
If I were wanting to sell a lot of shares I would give the share price a chance to breathe before putting more shares on the ask side. If it was allowed to bump up they could make more money per share!
Which brings us to the latest development.
On June 27, OWC announced that it has filed a patent application with the United States Patent and Trademark Office for the cream. This follows the filing of a provisional patent earlier this year.
The importance of this is that once granted, the patent will put the company in a position from which it can start to attract partners in both the development and the distribution of this asset. Prior to patent protection, this is difficult. Once protection is in place, it’s far easier.
And it is in this protection that we are rooting our medium-term bull thesis. In order to get this product on shelves and in the hands of as wide a patient population as possible, and as we’ve noted before, OWC would be far better collaborating with a deep-pocketed name as opposed to going it alone. The company doesn’t have too much cash on hand and any self-funded commercialization efforts would likely put pressure on shareholders from a dilution perspective (as OWC would have to raise to fund any such efforts).
The fact that the company is seeking to protect its asset right now suggests that it is looking to fall in line with the strategy we just described, which removes (in theory, at least) a large portion of dilutive risk from the equation for anybody thinking of picking up an exposure to this company and, specifically, this product, near term.
https://insiderfinancial.com/heres-whats-so-important-about-the-latest-owc-pharmaceutical-research-corp-otcmktsowcp-announcement
OWC Pharmaceutical Research Corp (OTCMKTS: OWCP) Gets Tough on Potential IP Thievery
By Michael Luke - July 13, 2017
In OWC Pharmaceutical Research Corp (OTCMKTS: OWCP) we have a stock that we’ve continually come back to cover time and time again here on Street Register, and we’ve got a couple reasons to do so today.
The developer of a proprietary active cannabinoid-based topical cream for psoriasis management which has been found to be highly effective, OWCP has taken steps to protect its intellectual property vis a vis that treatment in the European markets.
This week OWC Pharmaceutical Research Corp (OTCMKTS: OWCP) revealed that it had filed a patent application with the European Union Patent and Trademark Office for the active cannabinoid-based psoriasis topical cream. (The patent application number is EP 17178303.8)
This action by OWC is a key step in the Company’s continuing program to fully protect its intellectual property (IP). OWC’s strategy in seeking to fully protect its IP, including the filing of this European patent application will enable the Company to accelerate its ongoing discussions and negotiations regarding scientific, medical and commercial collaboration.
Commenting on the filing of the patent application, Mr. Mordechai Bignitz, Chairman and CEO of OWC Pharmaceutical Research, stated, “Our primary short-term objective is to introduce our topical cream for skin conditions including, most importantly, psoriasis to the market. Our necessity to fully protect our intellectual property limited our ability to provide potential customers and partners with the required data for their due diligence and review. Our proprietary data includes specifics regarding the formulation of the topical cream, consisting of cannabinoids and other compounds that facilitate the efficient delivery of the cream to infected areas. The filing of this European patent application also enables us to fully discuss with potential customers and partners the requirements for manufacturing the cream in accordance with national and local regulations. It also enables us to provide potential customers and partners with the manufacturing requirements, based on the highest-level of international standards and protocols, and includes specifics regarding the manufacturing process including required equipment and systems.”
Further commenting on the filing of the European patent application, Dr. Yehuda Baruch, the Company’s Chief Science Officer and OWC’s Director of Research and Regulatory Affairs stated, “The European market is very important to OWC and our product implementation strategy. Populous European countries including Germany, Italy, Spain and r Greece all have medical cannabis programs, and therefore are key markets for our psoriasis cream.” (Source: PR Newswire)
According to Global Data and the World Health Organization, the reported prevalence of psoriasis in countries ranges between 0.09% and 11.4%, making psoriasis a serious global problem with at least 100 million individuals affected worldwide. The global market of psoriasis treatments is expected to increase from a value of $6.6 billion in 2014 to more than $13.3 billion by 2024.
That leaves OWCP uniquely positioned to capitalize on a piece of that action, and protecting its portfolio is an important step in that process. One thing is for sure, with data suggesting that the company’s treatment improves the symptoms of psoriasis by as much as 70%, OWC Pharma is a name that could be set to grow in recognition considerably in years to come.
In the meantime, the stock itself is rebounding off of recent relative lows, so there is certainly short-term interest here as well.
http://streetregister.com/2017/07/13/owc-pharmaceutical-research-corp-otcmkts-owcp-gets-tough-on-potential-ip-thievery/
From 2 years ago...TEVA wanted to purchase OWCP's patents? WOW!
(JNi.media) Israeli Pharmaceutical company Teva appears to be moving into the medical marijuana market, and a pending acquisition could partially relieve the pain of its top drug, Copaxone, going off patent.
Teva, according to a report by The Marker, has made an offer for One World Cannabis (OWC) to purchase the rights to the company’s patents. One World is developing treatments using the compound in cannabis to treat chronic pain, multiple myeloma and other conditions.
http://www.jewishpress.com/news/breaking-news/teva-pharmaceuticals-thinks-its-high-time-for-medical-marijuana/2015/07/21/0/?print
These over the counter products won't have the effectiveness of OWCP's formula containing THC.
Cannabis and the human body have compatible cannabinoid systems that give cannabis its curative qualities for many human diseases.
"The present invention discloses a pharmaceutical composition comprising a therapeutically effective amount of at least one cannabinoid selected from the group consisting of: cannabidiol (CBD) or a derivative thereof, Tetrahydrocannabinol (THC) or a derivative thereof, and a combination thereof, useful for treatment or prevention of psoriasis. The present invention further discloses methods and uses of the aforementioned composition."
World Intellectual Property Organization list of OWCP patent applications...
https://patentscope.wipo.int/search/en/result.jsf?currentNavigationRow=next&prevCurrentNavigationRow=1&query=%22ONE%20WORLD%20CANNABIS%20LTD%22&office=&sortOption=Pub%20Date%20Desc&prevFilter=&maxRec=7&viewOption=All&listLengthOption=10
OWC Pharmaceutical Research Corp Releases Promising Preliminary Results From Efficacy Tests of its Topical Cream
Mar 21, 2017, 07:00 ET
OWC Pharmaceutical Research Corp. (OTCQB:OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of medical conditions and disorders, today announced the highly promising results of its topical cream efficacy tests following months of study and scientific analysis.
In October 2016, OWC announced that it was in the final phase of pre-clinical efficacy testing for its topical psoriasis cream and also announced a parallel test to assess the efficacy of the formulation in treating psoriasis in human skin tissue. The recent results are highly promising, showing significant reduction of several inflammation markers specific to psoriasis.
As a result of the promising results of our psoriasis tests, our Chairman and CEO, Mr. Mordechai Bignitz, has directed OWC's scientific team to submit an operating plan within 60 to 90 days to conduct double-blind efficacy tests of our cannabinoid-based topical cream on other skin disorders and conditions.
Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs, commented, "As a practicing physician and a scientist who has been treating patients with cannabis for medical purposes for more than two decades, I am truly excited by our success to date and, more importantly, I am thrilled to be part of a professional scientific study on humans that should actually validate what I have believed and experienced for years - Cannabis helps treat a multitude of health conditions."
Dr. Sharon Rozenblat, PhD - Biochemistry, a member of OWC Scientific Advisory Board added, "After many years of being actively involved in research and development of innovative dermatological treatments and being exposed to the many scientific articles and peer reviewed works and publications regarding skin conditions and diseases, I would like to emphasize my personal belief that OWC's psoriasis results have been indeed unique in the most positive sense." Dr. Rozenblat continued by stating, "While there is still scientific work to be done, as a scientist I am extremely excited to be part of OWC's study that appears to become a highly possible breakthrough that can improve the life of psoriasis patients and, possibly, other skin conditions."
Mr. Mordechai Bignitz, the Company's Chairman and CEO, stated that, "Immediately after we announced our cannabinoid-based formulation for our psoriasis treatment, we began receiving requests for the topical psoriasis cream from patients who had been long-time sufferers from the condition. We are very pleased to say that OWC is expecting the topical cream product readiness during 2017 Q2 and, subject to positive completion of our safety IRB approved study and obtaining regulatory approvals from applicable jurisdictions, we should be able to offer our topical cream to those who suffer from psoriasis in the near term."
http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-releases-promising-preliminary-results-from-efficacy-tests-of-its-topical-cream-616697214.html
I just thought I'd post that article from February because it has a lot of positives for OWCP in it.
Those results will be very interesting for shareholders!
I'll be waiting patiently for that day...
OWC Pharmaceutical Research Corp Receives IRB Approval To Initiate Safety Testing On Its Cannabinoid-Infused Cream For Treatment Of Psoriasis
Feb 27, 2017 7:00 AM EST
PETACH TIKVA, Israel, February 27, 2017 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical crème compound for the treatment of psoriasis and related skin conditions. The approval follows the Company's February 1, 2017 8K filing announcing an extension to the size and scope of its efficacy study on the same compound, which began in November 2106.
The IRB approved study encompasses the cream itself, as a delivery mechanism, as well as the proprietary psoriasis formulation, and is the first to formally make such claims with the NIH Registry. The double-blind study, which will be conducted on healthy volunteers at one of Israel's leading academic hospitals, is designed to demonstrate the safety of the formulation in treating psoriasis on human skin tissue. Administrators began soliciting for study participants as soon as approval was received.
Dr. Yehuda Baruch, the Company's Director of Research and Regulatory Affairs, commented on the announcement, "This approval is a significant milestone for OWC, where our mission is to bring the same rigorous approach common to traditional pharmaceutical development to the medical cannabis field. As we reported earlier this year, the results of our efficacy studies were so encouraging that management decided it was in our interest to extend the size and scope of the study to check the biological markers that had been generated to date, among other things. "
Dr. Baruch went on to say, "With each study we conduct, the ability of our formulation to provide relief for psoriasis-related symptoms to patients suffering from the condition are substantiated. The study that was just approved was designed to assure patients and caregivers that it is safe to use outside of laboratory conditions."
https://www.thestreet.com/story/14016621/1/owc-pharmaceutical-research-corp-receives-irb-approval-to-initiate-safety-testing-on-its-cannabinoid-infused-cream-for-treatment-of-psoriasis.html
Good video!
It's a crime how this plant has been ignored for so long!
How much relief could this have brought to the world?
Don't forget that CBIS has 8 more months of collaboration with Dana/Farber after the April update.
Lots of time for additional discovery during that time.
30 what?
Here's your 8-k
https://seekingalpha.com/filing/3492643
CBIS Subsidiary, Cannabis Science Europe GmbH Acquires Majority Shares of German Bio Med GmbH Jinvator to Facilitate European Expansions, New Products, and Additional Clinical Studies
The Ground-Breaking Jinvator nanoGold test is the first and only early diagnostic test for HIV/AIDS! The nanoGold test gives HIV/AIDS no chance!
IRVINE, CA- (April 5, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in cannabis formulation-based drug development, is pleased to announce its subsidiary Cannabis Science Europe GmbH (CBIS EU) has acquired 74.9% of a German Bio Med Corporation “Jinvator Bio Med GmbH” (Jinvator), the creator of an ultra-sensitive rapid HIV/AIDS test based on nano-particle technology for the detection of HIV in the early stage of infection.
CBIS EU and Jinvator have agreed to immediately refine, develop, and bring the nanoGold test to market – a product that expedites early HIV-testing without the risk of diagnostic gaps. Both Companies will mutually share the development of intellectual property and innovative advancements of bringing the technology to consumers now.
HIV/AIDS is one of the most severe epidemics of modern times, affecting 34 million patients globally. The prospect of being cured increases with early detection. Recent studies have shown that newborns, when timely diagnosed, can be cured from HIV/AIDS. Despite current tests being able to detect HIV within three months of infection with a 99% chance, the 1% uncertainty factor still remains. The nanoGold test aims to eliminate that risk by using nanotechnology to safely diagnose HIV within one week of infection. The highly-sensitive nanoGold test has the capability to detect a single virus in blood or saliva with a 10,000-fold dilution. The test is also suitable for diagnosing HIV in newborn babies.
"There is an enormous market for the nanoGold test, ranging from the general public, to diagnostic laboratories, blood banks, and hospitals. As an original and unrivaled testing kit designed for convenience and quick diagnosis, there is opportunity for the product to be well-received globally. In addition, the nanoGold test is produced to be more cost-effective for the consumer, in contrast to other related products on the market. Moreover, it can be performed and evaluated easily without technical aids,” stated Jinvator President, Dr. R. S. Bhardwaj."
About Jinvator Bio Med GmbH
The Canadian Medical MJ ETF did start trading today HMMJ.TO about $10 a share.
The American version, Emerging AgroSphere ETF, is not out yet but hopefully won't take much longer.
That will tighten up the shares of CBIS for sure!
Look. There are many things going on with CBIS that aren't put to your approval before they happen. You can't know what activities are happening until they want you to know.
There are many aspects of the kind of business they are in that must be kept out of the public and government eye.
Yes, they do have product in dispensaries now which will mean much better revenue numbers and getting better for years to come!
April should be the month that CBIS shows it's true potential and investors eat up the these cheap shares at a much faster pace.
I checked that out and it looks like CBIS has an untouchable supply for products and research for years to come!
That should give shareholders some real peace of mind.
I'm sure the Tribe loves the deal as well. They are taking advantage of present day U.S. laws concerning cannabis and will make a fortune for their people. Good for them and CBIS.
Thanks for the assurance of my investment. Let's make some money!
CBIS Appoints Leader of Global Health Information Julia Royall to Its Scientific Advisory Board
IRVINE, CA--(Marketwired - Mar 30, 2017) - Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in cannabis formulation-based drug development, today announced that leader of global health information, Ms. Julia Royall, has been appointed to the Scientific Advisory Board of CBIS.
Ms. Royall is a Member of the Scientific Advisory Board. As a specialized consultant, she will provide advice and expertise on health information databases, management systems, and Internet technology. Julia Royall is a leader in health information and has been working in international health in Africa since 1990, with more than 40 years of professional experience in the communications field. Julia's commitment is to bring together information and technology with partners, projects and funding, using a variety of media.
Ms. Royall was recruited to the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in 1997 to create a malaria research communications network (MIMCom) to support scientists in Africa as part of the Multilateral Initiative on Malaria. The first network of its kind, MIMCom comprised 27 research sites in 14 African countries and engaged over 30 partner organizations and institutions in the US, UK, Europe, and Africa.
As Chief of NLM's Office of International Programs, she created innovative programs which focused on Africa and comprised outreach to medical librarians, medical journal editors, researchers, medical students, and health workers at the village level. In addition to adapting NLM databases for use in Africa, her work has encompassed a variety of media -- from web-based interactive digital tutorials to posters and video. Under Ms. Royall's leadership, NLM developed greater focus on global health by piloting demonstration projects which drew strength from one another and tied into NLM's major programs and databases.
Prior to government service, she was Deputy Director of SatelLife, a nonprofit dedicated to satellite delivery of public health and medical information in developing countries. As part of the team setting up the first Internet connections for health in sub Saharan Africa, she initiated and directed the HealthNet Information Service. HealthNet News was the first electronic health publication on the continent, published weekly for 20 years and pioneered digital sharing of medical literature in medical schools of sub Saharan Africa.
In 2007 - 2008, she was Fulbright Scholar to Uganda, based in the Office of the Dean at Makerere University, and has since served as a Fulbright Specialist at Kenyatta University in the Office of the Vice Chancellor.
Retired from U.S. Government service, she is currently principal investigator for the African Digital Health Library (ADHL), funded by the Office of Global AIDS Coordinator/U.S. Department of State. Based at 5 universities across Africa, ADHL will showcase in-country research previously not digitally accessible. She is also developing an African Student Innovation Fund with Carnegie Mellon University's Africa campus in Kigali, Rwanda.
http://finance.yahoo.com/news/cbis-appoints-leader-global-health-150842070.html
There you go saying 22 "convictions".
You need to learn the definition of a conviction.
A conviction comes if a felony has been committed. There were no felonies committed therefore no criminal court.
Civil court is where white collar matters are handled.
What I believe is Raymond Dabney has been the CEO at CBIS for 9 years and has learned to not cross the line to cause those types of problems from the past.
You can keep on like a loop on this old matter but I am looking toward the future of CBIS!
Well, since you erased your original message I should point out that you had stated they only had product in one dispensary.
That was misleading so I wanted to get the correct information!
I will verify all dispensaries listed are carrying CBIS products today.
"Our in-house database will form the basis of patient-centered outcomes research (PCOR) for a variety of critical conditions."
CBIS is keeping records of the effectiveness of their products through a targeted observational study.
I think that's a very smart way to gleen information to help with future production changes and update interested parties with results of the study.
I did call yesterday and received this response soon afterward. Four total dispensaries.
Concerning the greenhouses, don't you think if they paid $201,000 to Dana/Farber that they would have the money to build a couple of greenhouses? They will have to have plants to do the research on, right?
Response from Cannabis Science:
I am following up from our phone call earlier today. Cannabis Science products can be found at the medical dispensaries listed below:
MedMen
8208 Santa Monica Blvd
West Hollywood, CA, 90046
323-848-7981
info@MedMen.com
BARC (Beverly Alternative Relief Collective)
432 S. San Vicente Blvd. Suite #100
Los Angeles, CA, 90048
(855) 227-2420
barcc432@gmail.com
Med X
1445 W Century Blvd
Los Angeles, CA 90947
Moonlight Cannabis Collective
5801 E. Beverly Boulevard
Suite 100
East Los Angeles, CA 90022
(760) 985-5592
Please note that you would need a valid medical marijuana ID to make any purchases. I would also suggest calling ahead to confirm if they have the product in store beforehand.
You may also direct any investor-related questions to our Investor Relations Officer, Teresa Misenheimer, at teresa@cannabisscience.com.
If you have any other questions, please do not hesitate to ask us.
Best Regards,
xxxxx
Cannabis Science, Inc.
IRVINE, CA--(Marketwired - Mar 27, 2017) - Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that it has substantially increased its production for its self-medicating patient product line distributed through cannabis dispensaries in California. CBIS moves to meet the outstanding influx of self-medicating patient requests as it highlights Moonlight Cannabis as its Newest Spotlight Dispensary for the Month of April 2017.
Moonlight Cannabis is the CBIS April 2017 Spotlight Dispensary in the Los Angeles area.
5801 E. Beverly Blvd., Suite 100
Los Angeles, CA 90022
T. 323.834.9420
E. moonlightbevery@gmail.com
"Moonlight Cannabis has no
http://finance.yahoo.com/news/cbis-ramps-production-releases-more-194040110.html
sico,
It seems that you have the facts misconstrued.
You said, "....paying big bucks to speak at the danafarber conference".
They paid two hundred thousand dollars to collaborate for one year with The Dana/Farber Cancer Institute on proving cannabis compound benefits for multiple ailments and diseases.
The CEO will be a keynote speaker at The Global Health Catalyst Summit at Harvard Medical School April 28-30 next month.
It sounds different when stated truthfully.
sico,
I think the party is just getting started!
They made it through the last several tough years to get to these times that are quickly changing in favor of medical cannabis.
The momentum is just picking up and I think you know that, too.
Shortsellers beware!
April showers bring cannabis flowers...of profit!
I believe and read how cannabis is used for pain very successfully.
I believe we will be enlightened by the CEO next month in a very good way concerning the progress of the company and the collaboration with Dana/Farber.
This is reinforced by how hard some try to scare us out...A very good sign that they are very nervous about the good news around the corner.
I think the article was written very well!
CBIS is generating revenues now and that is not what the shortsellers want to see!
The next update will be just what the doctor ordered for the longs to get healthy!
Another article touting the CBIS Patch...
http://healthtips365.com/revolutionary-cannabis-patch-successfully-treats-fibromyalgia-diabetic-nerve-pain/#respond
Medical pot bill in S. Carolina bolstered by conservatives
By SEANNA ADCOX, ASSOCIATED PRESS COLUMBIA, S.C. — Mar 26, 2017, 10:29 AM ET
South Carolina Rep. Eric Bedingfield once shunned all marijuana use, but when his eldest son's six-year struggle with opioid addiction ended with his overdose a year ago, the conservative Republican co-sponsored medical cannabis legislation.
"My mindset has changed from somebody who looked down on it as a negative substance to saying, 'This has benefits,'" Bedingfield said recently.
The 50-year-old teetotaler believes marijuana may effectively wean addicts from an opioid dependence. Ultimately, the Marine veteran hopes medical marijuana can be an alternative to people being prescribed OxyContin or other opioid painkillers to begin with, helping curb an epidemic he's seen destroy families of all economic levels.
Two decades after California became the first state to legalize medical marijuana, efforts to let patients legally access pot are slowly taking root in the South.
While 28 states allow comprehensive medical marijuana programs, only two of those are in the South. Arkansas and Florida voters approved theirs through the ballot last November. Neither is in place yet. A law signed in Louisiana last year, also not yet in effect, doesn't allow the smoking or vaping of marijuana.
This year's renewed push in South Carolina is bolstered by some of the state's most conservative legislators, such as Bedingfield, whose opinions have shifted due to personal losses or the pleadings of parents and pastors in their districts.
Three years ago, state lawmakers passed a very narrow law allowing patients with severe epilepsy, or their caregivers, to legally possess cannabidiol, or CBD, a non-psychoactive oil derived from marijuana. Bedingfield voted against that idea.
Bill Davis, a Christian author who leads a Bible study for people fighting drug addiction, said he was bedridden before trying marijuana. Diagnosed two years ago with idiopathic pulmonary fibrosis, a lung disease with no cure, he was put on an experimental drug with "horrible side effects."
"I had to decide whether I wanted to die of lung disease or kidney or liver failure," Davis said.
Then he started vaping marijuana, which he says allows him to control the amount of CBD and THC he receives.
"I'm praying this state will allow me to be treated legally for me to live" using "a plant that God made," he said.
Republican Rep. Jonathon Hill said he signed onto the bill after hearing Davis' story over dinner at his home.
"He is living, walking proof that there can be some very real benefits," he said.
A bill allowing people with a debilitating medical condition, or their adult caregivers, to legally possess 2 ounces (57 grams) of marijuana advanced last month to the House's full medical committee. Its Republican backers tout the bill's "seed-to-sale tracking" as guarding against recreational use. A Senate subcommittee is considering an identical bill.
"We shouldn't be forcing a choice between breaking the law or not taking care of members of your family," said Republican Rep. Bill Herbkersman.
Marijuana was the only thing that gave his brother an appetite and kept the pain at bay before he died of skin cancer in 2011, Herbkersman said.
"They call it a gateway drug, but sometimes it's just a gateway to a little bit better life, or what you have left of a life," he said.
The idea still has strong opposition — chiefly from South Carolina's law enforcement agencies, including State Law Enforcement Division Chief Mark Keel.
Jarrod Bruder, director of the state Sheriffs' Association, told the House panel that sheriffs can't support legalizing a drug the federal government still puts in the same class as heroin and cocaine.
His predecessor, however, stunned observers when he stood to support the bill.
Jeff Moore, who retired in 2014 after 32 years leading the association, credits marijuana with saving his son's life. But he says it also prevents his son, an Army veteran, from coming home to South Carolina for fear of being arrested.
In 2008, six weeks into his son's first of two tours in Iraq, their convoy was surrounded in Mosul. He watched as five of his friends were killed by an IED and he fought for his life for 2 ? hours. He suffers from PTSD and traumatic brain injury as that battle scene and others replay in his mind. He was honorably discharged after two suicide attempts, Moore said.
Eventually, his son's father-in-law, a Vietnam veteran, convinced him to move near him in Michigan, where he can legally smoke a high-CBD, low-THC strain of marijuana Moore says does not get him high. He's stopped drinking, returned to college and organized an all-veteran support group. He is also an elder in his church, Moore said.
"His life has made a complete, 180-degree turnaround. Had he stayed in South Carolina, he'd have ended up killing himself," Moore said.
http://abcnews.go.com/Health/wireStory/medical-pot-bill-carolina-bolstered-conservatives-46382819
Natural Healing Magazine had a good article about the CBIS patch...
http://www.naturalhealingmagazine.com/revolutionary-cannabis-patch-successfully-treats-fibromyalgia-diabetic-nerve-pain/
IRVINE, CA--(Marketwired - Oct 26, 2016) - Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabis-based medicines, today announced it has just signed a new agreement that will provide an additional 320 acres of allotment development land in Humboldt County, Nevada. Along with production growing and processing operations, this agreement will integrate drug development, educational development, and commercial enhancements for job creation within their respective communities.
Chief Bill, stated, "We are very pleased to be working with Cannabis Science on such large scale projects. I am a member of the Allotment Family Members of Northern Nevada / Idaho Shoshoni. I Represent the Allotment Families of the Winnemucca Tribe MBS. The Tribal Allotment Families of Winnemucca covers several reservations with a total of over 5,000 acres covering several States. We signed the original deal in Ft. McDermitt allotment with the goal to bring education, the job creation and drug development programs and now this land package, as we strive to bring each tribe across the Country the same opportunity for their own economic community development. Because one of our group members already has an Industrial Hemp Research Permit and Department of Agriculture Certificate (License) in place (on one of our properties) in Southern Nevada our expansion plans are going very smoothly. We are in development (production) and expect to be in production with Cannabis Science in short order. I am in discussions with several other tribes across the nation and I expect Raymond's vision and expertise will continue to be the architect helping us realize our aggressive growth plans and we are looking forward to it."
This Agreement between CBIS and its contributing affiliates will facilitate outdoor and indoor operations when it comes to Hemp and Medical Marijuana, as native law permits in this specific location, with applicable licensing. All parties involved are motivated and excited with all the possibilities brought forward with this new Agreement. It gives CBIS and its investor partners access to over 300 acres in development land. Considering the size and diversity of this project, the partners needed to act in different segments with their own respective area of expertise to locate the ideal spots to commence key operations for this land package.
"This added capacity will not only benefit CBIS and it's contributing affiliates, but also the Community with the educational component. The profound benefits are multiplied from this Agreement in many ways, including current research and programs targeting critical ailments including Cancer, PTSD, HIV/AIDS, Autism, and Neurological disorders, utilizing and monitoring different cannabinoid formulations and delivery modules. Working with Chief Bill, CBIS will have a much wider base to work from by further expanding into the State of Nevada, drawing another very large targeted medical consumer base. This Nevada opportunity was a complete surprise as we were more focused on targeting California expansions; however, of course, when new and fortuitous circumstances present themselves, you must be fluid, and open to respond accordingly. This is what we did. The added capacity this development deal and others like it should allow us to rapidly move from into a much larger development and production capacity to continue the advancement of our drug development programs while we provide our important formulations to patients in need, sooner and in greater geographic areas. We are expanding across the Nation," stated Cannabis Science President & CEO, Co-Founder Raymond C. Dabney.
http://finance.yahoo.com/news/cannabis-science-signs-320-acre-120244472.html
Didn't sicofbs say that there is no Chief Bill Bills whom Cannabis Science signed a deal with for land in Nevada for greenhouses and production facilities?
Here's proof that sicofbs is wrong:
Chief William Bills
In 1971 The United States Government recognized the Winnemucca Indian Colony as a Federally
Recognized Reservation, near Winnemucca, Nevada.
In 1998 The Current Chairman, William Bills became Vice-Chairman of the Winnemucca Indian Colony of
Nevada.
On April 17, 2000 William Bills became Official Chairman.
Chief William Bills is steadfastly and diligently pursuing multiple economic development opportunities,
including, Manufacturing, Import/Export, Renewable Energy and I-Gaming.
https://winnemuccaindiancolonyofnevada-nsn.gov/index.php/government
I would like some proof, otc...
It will take a big pharma to do it!
It will make the stock go up if someone starts bidding on it.
obiwan, YOU ROCK!!!
They will release their 10-K in April or May like last year.
sicofbs, you seem to think CBIS is not doing anything but with the laws changing for the better we will see the progress being made.
The $201,000 they paid to Dana/Farber wasn't anything to sneeze at, was it?
A little longer from here and you will see...